{"status": "ok", "totalResults": 355, "articles": [{"source": {"id": "techcrunch", "name": "TechCrunch"}, "author": "Kate Clark", "title": "Indigo raises $250M, launches marketplace to help farmers get paid for quality grain", "description": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026", "url": "http://techcrunch.com/2018/09/18/indigo-raises-250m-launches-marketplace-to-help-farmers-get-paid-for-quality-grain/", "urlToImage": "https://techcrunch.com/wp-content/uploads/2018/09/Indigo_Wheat1.jpeg?w=600", "publishedAt": "2018-09-18T13:00:15Z", "content": "Indigo, the startup bringing algorithms and machine learning to the agricultural industry, has raised a $250 million Series E, bringing its total raised to $650 million. The funding values the company at $3.5 billion, according to a source familiar with the d\u2026 [+2449 chars]"}, {"source": {"id": "business-insider", "name": "Business Insider"}, "author": "Lydia Ramsey and Charlotte Hu", "title": "The Trump administration's top health official isn't counting on pharma to bring down drug prices", "description": "Health and Human Services Secretary Alex Azar isn't counting on pharmaceutical companies to do the right thing when it comes to drug prices. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharma Pricing Summit on \u2026", "url": "https://www.businessinsider.com/hhs-secretary-alex-azar-on-drug-pricing-2018-9", "urlToImage": "https://amp.businessinsider.com/images/5a1ee1183dbef484008b8f22-2732-1366.jpg", "publishedAt": "2018-09-13T14:34:06Z", "content": "Department of Health and Human Services Secretary Alex Azar isn't banking on the pharmaceutical industry to fix the rising cost of prescription drugs in the US. \"I'm not counting on their altruism or their cooperation,\" Azar said at the Financial Times' Pharm\u2026 [+1364 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (George Budwell)", "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://www.fool.com/investing/2018/09/07/why-exact-sciences-corporation-stock-rocketed-high.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493775%2Frocketman.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences ( NASDAQ:EXAS ), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-\u2026 [+1929 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://www.fool.com/investing/2018/09/06/3-top-big-pharma-stocks-to-buy-now.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493451%2Fpharmaceutical-research.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4543 chars]"}, {"source": {"id": "bloomberg", "name": "Bloomberg"}, "author": null, "title": "Pfizer to Idle Plants in North Carolina With Hurricane Florence Approaching", "description": null, "url": "https://www.bloomberg.com/tosv2.html?vid=&uuid=ec67c3a0-b5ed-11e8-a686-d35d83610e7e&url=L25ld3MvYXJ0aWNsZXMvMjAxOC0wOS0xMS9wZml6ZXItdG8taWRsZS1wbGFudHMtaW4tbm9ydGgtY2Fyb2xpbmEtYXMtaHVycmljYW5lLWFwcHJvYWNoZXM=", "urlToImage": null, "publishedAt": "2018-09-11T17:07:37Z", "content": "Your usage has been flagged as a violation of our terms of service. For inquiries related to this message please contact support. For sales inquiries, please visit http://www.bloomberg.com/professional/request-demo If you believe this to be in error, please c\u2026 [+280 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "Trefis Team, Contributor, Trefis Team, Contributor https://www.forbes.com/sites/greatspeculations/people/trefis/", "title": "A Look At Pfizer's Business And Outlook", "description": "Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, Anti-Infective, Alimentary &amp;Metabolism, Neuroscience, Immunology drugs, along with its Legacy Pharma, Consumer, Biosimilar &amp; Other segment. Legacy Pharma, Consumer, Biosimilar\u2026", "url": "https://www.forbes.com/sites/greatspeculations/2018/09/10/a-look-at-pfizers-business-and-outlook/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fblogs-images.forbes.com%2Fthumbnails%2Fblog_25%2Fpt_25_188249_o.jpg%3Ft%3D1536604325", "publishedAt": "2018-09-10T18:32:00Z", "content": "Share to facebook Share to twitter Share to linkedin The Pfizer company logo is photographed at Pfizer Inc. headquarters, in New York, Monday, Dec. 4, 2017. (AP Photo/Richard Drew) Pfizer (NYSE:PFE) generates its revenues from its Oncology, Cardiovascular, An\u2026 [+9107 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Why Exact Sciences Corporation Stock Rocketed Higher in August", "description": "Exact Sciences' stock got a major boost from a partnering deal with pharma titan Pfizer last month.", "url": "https://finance.yahoo.com/news/why-exact-sciences-corporation-stock-100000965.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/cuXO7YplZxOVKts6hNDIHw--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/motleyfool.com/e4f07b38fce926e7eda0457056f7069a", "publishedAt": "2018-09-07T10:00:00Z", "content": "What happened Exact Sciences (NASDAQ: EXAS), a mid-cap cancer diagnostic company, saw its shares gain a healthy 26.7% last month, according to data from S&amp;P Global Market Intelligence. The spark? Exact Sciences' shares powered higher in response to a co-m\u2026 [+2147 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Is Bristol-Myers Squibb Company a Buy?", "description": "This big pharma stock has some baggage, but it also claims two fast-growing blockbusters.", "url": "https://www.fool.com/investing/2018/09/09/is-bristol-myers-squibb-company-a-buy.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493827%2Fpills-foming-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-09T10:31:00Z", "content": "Bristol-Myers Squibb ( NYSE:BMY ) stock has underperformed the S&amp;P 500 index so far this year. It's also trailed well behind most of its peers, but it could be worse. Earlier in 2018, Bristol-Myers Squibb (BMS) was down 17%; now the stock has climbed back\u2026 [+3494 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know", "description": "Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.", "url": "https://finance.yahoo.com/news/pfizer-pfe-outpaces-stock-market-214509813.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/1MpaQeAGbKW4njUAW3XfGw--~B/aD00MjE7dz02MzU7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1154d43aaeb65735a640003549116295", "publishedAt": "2018-09-14T21:45:09Z", "content": "In the latest trading session, Pfizer (PFE) closed at $42.97, marking a +0.34% move from the previous day. This change outpaced the S&amp;P 500's 0.03% gain on the day. At the same time, the Dow added 0.03%, and the tech-heavy Nasdaq lost 0.05%. Coming into t\u2026 [+2831 chars]"}, {"source": {"id": null, "name": "Nejm.org"}, "author": "Kim Papp, Kenneth Gordon, Diamant Tha\u00e7i, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G. Girgis, Sudeep Kundu, Subhashis Banerjee", "title": "Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "description": "Original Article from The New England Journal of Medicine \u2014 Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1806382", "urlToImage": "https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/0/nejm.ahead-of-print/nejmoa1806382/20180907/images/img_small/nejmoa1806382_f1.jpeg", "publishedAt": "2018-09-12T06:00:02Z", "content": "Supported by Bristol-Myers Squibb. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Papp reports receiving grant support, consulting fees, advisory board fees, and fees for serving on a speakers\u2019 burea\u2026 [+4079 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Lilly, Teva, Pfizer & Others Await FDA Decisions in September", "description": "FDA grants approval to 34 new treatments this year so far.", "url": "https://finance.yahoo.com/news/lilly-teva-pfizer-others-await-125812067.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/EyZmh1klWYX.2_4cspNDgQ--~B/aD00MTM7dz02MjA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/zacks.com/1c294b9de375a124a76eae049179f11e", "publishedAt": "2018-09-07T12:58:12Z", "content": "Like 2017, 2018 is turning out to be a pretty good one for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 34 novel drugs till August. Last year, the FDA had given nod to 31 new drugs till August and approved 46 d\u2026 [+4154 chars]"}, {"source": {"id": null, "name": "Forbes.com"}, "author": "John Dorfman, Contributor, John Dorfman, Contributor https://www.forbes.com/sites/johndorfman/", "title": "Apple, Berkshire, Pfizer And 17 Other Large-Cap Buy And Sell Recommendations", "description": "Many investors favor large-caps. Here are recommendations on the 20 largest U.S. stocks..", "url": "https://www.forbes.com/sites/johndorfman/2018/09/17/apple-berkshire-pfizer-and-17-other-large-cap-buy-and-sell-recommendations/", "urlToImage": "https://thumbor.forbes.com/thumbor/600x315/https%3A%2F%2Fspecials-images.forbesimg.com%2Fdam%2Fimageserve%2Fa4969b25b24e467aa4db4387435f0b88%2F960x0.jpg%3Ffit%3Dscale", "publishedAt": "2018-09-17T14:27:00Z", "content": "Share to facebook Share to twitter Share to linkedin The iPhone XS (left) and XS Max (AP Photo/Marcio Jose Sanchez) My bread and butter are small-cap and mid-cap stocks. But many people stick to the largest stocks, so once a year I offer my buy and sell recom\u2026 [+9972 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "Pfizer's Skin Disease Drug Gets Breakthrough Therapy Status", "description": "Pfizer's (PFE) investigational oral JAK3 inhibitor PF-06651600 gets Breakthrough Therapy designation from the FDA for alopecia areata.", "url": "https://finance.yahoo.com/news/pfizer-apos-skin-disease-drug-145702447.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/RcSGEOiRo4N.qL406x4Pog--~B/dz0wO3NtPTE7YXBwaWQ9eXRhY2h5b24-/http://media.zenfs.com/en-US/homerun/zacks.com/df5ad064f24e5502d8d1fb68bd8dc90d", "publishedAt": "2018-09-06T14:57:02Z", "content": "Pfizer, Inc. PFE announced that it has received Breakthrough Therapy designation for its pipeline candidate, PF-06651600 from the FDA. The candidate is being developed for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, \u2026 [+3625 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "VCDeals", "title": "Pfizer Invests In Mini Brains, Kleiner Perkins Splits", "description": "Welcome to Seeking Alpha\u2019s Venture Capital Deals of the Week. Follow this account and turn on the e-mail alert to receive VCDeals in your inbox on Saturday morn", "url": "https://seekingalpha.com/article/4206471-pfizer-invests-mini-brains-kleiner-perkins-splits", "urlToImage": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "publishedAt": "2018-09-15T14:21:49Z", "content": "Online used car marketplace: Goldman Sachs (NYSE: GS ) Investment Partners and BMW ( OTCPK:BMWYY ) i Ventures participated in a $140M Series D round for Shift, an online marketplace for used cars. The round included equity and debt. Lithia Motors led and CEO \u2026 [+4371 chars]"}, {"source": {"id": null, "name": "Yahoo.com"}, "author": null, "title": "3 Top Big Pharma Stocks to Buy Now", "description": "Great dividends and great growth prospects make these big pharma stocks great picks for long-term investors.", "url": "https://finance.yahoo.com/news/3-top-big-pharma-stocks-103000865.html", "urlToImage": "https://s.yimg.com/uu/api/res/1.2/dMhJrTHQFTunhg6UyrJWsA--~B/aD0zODc7dz01ODA7c209MTthcHBpZD15dGFjaHlvbg--/http://media.zenfs.com/en-US/homerun/motleyfool.com/cac2a8c273ac939ed15d71ebb32efe02", "publishedAt": "2018-09-06T10:30:00Z", "content": "Some people stick the word \"big\" in front of an industry name in an effort to disparage the largest players in that particular market. When I use the term \"big pharma,\" though, I'm not intending to be derogatory. My use of the label is to simply refer to the \u2026 [+4838 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Cory Renauer)", "title": "Sangamo's Zinc Fingers Fail Again. Time to Walk Away?", "description": "Here's what investors need to know about the disappointing results Sangamo announced recently.", "url": "https://www.fool.com/investing/2018/09/06/sangamos-zinc-fingers-fail-again-time-to-walk-away.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493528%2Fbusinessman-in-shock-hands-on-head-laptop-surprise-investment-getty.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T12:48:00Z", "content": "An attempt to edit genetic flaws on the fly didn't work nearly as well as hoped for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ), and the stock just took a dip. Is it time to cut and run? Before investors do any panic trading, there are a few things they need t\u2026 [+4435 chars]"}, {"source": {"id": null, "name": "Fiercebiotech.com"}, "author": "Nick Paul", "title": "After midphase flop, Pfizer taps Cytoo for help identifying DMD targets", "description": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data.", "url": "https://www.fiercebiotech.com/biotech/after-midphase-flop-pfizer-taps-cytoo-for-help-identifying-dmd-targets?utm_source=internal&utm_medium=rss", "urlToImage": "https://qtxasset.com/fiercebiotech/1536316463/PfizerHQsignone.jpg/PfizerHQsignone.jpg?vOOHCcNj1UrRzDdMkYiDtHlm6yj70xsd", "publishedAt": "2018-09-07T10:35:16Z", "content": "Pfizer has teamed up with Cytoo to work on a Duchenne muscular dystrophy (DMD) target discovery platform. The early-stage alliance (PDF) comes a week after Pfizer halted development of domagrozumab in DMD because of lackluster midphase data. Domagrozumab\u2019s in\u2026 [+1963 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Buy Pfizer; target of Rs 3100: Centrum", "description": "Centrum recommended hold rating on Pfizer with a target price of Rs 3100 in its research report dated September 10, 2018.", "url": "https://www.moneycontrol.com/news/business/stocks/buy-pfizer-target-of-rs-3100-centrum-2944591.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2017/03/hold1-770x433.jpg", "publishedAt": "2018-09-12T10:43:03Z", "content": "Centrum's research report on Pfizer We downgrade Pfizer to Hold from Buy rating and retain our TP of Rs3,100 (earlier Rs2,900), based on 23x March\u201920E EPS of Rs134.6 due to its rich valuations. Pfizer share price has moved rapidly in the recent past necessiti\u2026 [+976 chars]"}, {"source": {"id": "vice-news", "name": "Vice News"}, "author": "Maia Szalavitz, Matt Taylor", "title": "Big Pharma's Opioid Greed Was Even Worse Than We Thought", "description": "\"The Sackler family is just as shameless, and only marginally less ruthless, than the drug cartels.\"", "url": "https://www.vice.com/en_us/article/7xj97q/big-pharmas-opioid-greed-was-even-worse-than-we-thought", "urlToImage": "https://video-images.vice.com/articles/5b9a7d0ea695b9000627ab6a/lede/1536865021610-oxy-cash2.jpeg?crop=1xw:1xh;center,center&resize=1200:*", "publishedAt": "2018-09-13T19:41:38Z", "content": "Left Image: Photo by George Frey/Bloomberg via Getty Images. Right Image: Adam Gault/Getty Images The chutzpah was almost impressive. A member of the Sackler family that owns Purdue Pharma \u2014the notorious manufacturer of Oxycontin \u2014recently patented a new form\u2026 [+7325 chars]"}, {"source": {"id": null, "name": "Fool.com"}, "author": "newsfeedback@fool.com (Keith Speights)", "title": "Why Sangamo Therapeutics, Inc. Sank Again Today", "description": "Disappointing interim results for its gene-editing therapy continued to weigh on the biotech stock.", "url": "https://www.fool.com/investing/2018/09/06/why-sangamo-therapeutics-inc-sank-again-today.aspx", "urlToImage": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F493757%2Fdoctor-with-dna-and-question-mark.jpg&h=630&w=1200&op=resize", "publishedAt": "2018-09-06T21:00:00Z", "content": "What happened Shares of Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) were down 10.5% as of 3:34 p.m. EDT on Thursday. This marked the second consecutive day of double-digit percentage declines following the biotech's interim update from a phase 1/2 clinical stu\u2026 [+2158 chars]"}]}